Visceral adiposity is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-10-31. Numbers and descriptions here follow the published literature rather than marketing material.
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
| Property | Value | Notes |
|---|---|---|
| 分子类型 | 合成肽 | 含 44 个氨基酸残基的 GHRH 类似物 |
| N 端修饰 | 反式-3-己烯酰基 | 用于抵抗二肽基肽酶 IV 降解 |
| 首次批准 | 2010 年，美国 | 用于 HIV 相关脂肪营养不良 |
| 作用靶点 | 生长激素释放激素受体 | 位于垂体前叶 |
| 主要研究终点 | 内脏脂肪变化 | 非总体重或瘦体重 |
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
Blood levels necessary to cause adverse effects in adults are thought to be greater than about 150 ng/mL. An excess of vitamin D causes hypercalcaemia (high blood concentrations of calcium), which can cause overcalcification of the bones and soft tissues including arteries, heart, and kidneys. Untreated, this can lead to irreversible kidney failure. Symptoms of vitamin D toxicity may include the following: increased thirst, increased urination, nausea, vomiting, diarrhea, decreased appetite, irritability, constipation, fatigue, muscle weakness, and insomnia. In 2011, the US National Academy of Medicine revised tolerable upper intake levels (UL) to protect against vitamin D toxicity. Before the revision the UL for ages 9+ years was 50 μg/d (2000 IU/d). Per the revision: "UL is defined as "the highest average daily intake of a nutrient that is likely to pose no risk of adverse health effects for nearly all persons in the general population". The US ULs in micrograms (mcg or μg) and international units (IU) for both males and females, by age, are:
Elizabeth Broadbent; Keith J Petrie; Jodie Main; John Weinman (2006). "The brief illness perception questionnaire". Journal of Psychosomatic Research. 60 (6): 631–637. doi:10.1016/j.jpsychores.2005.10.020. PMID 16731240. Wikidata Q50936509. Elizabeth Broadbent; Carissa Wilkes; Heidi Koschwanez; John Weinman; Sam Norton; Keith J Petrie (2015). "A systematic review and meta-analysis of the Brief Illness Perception Questionnaire". Psychology & Health. 30 (11): 1361–1385. doi:10.1080/08870446.2015.1070851. PMID 26181764. Wikidata Q38548518. E. Broadbent; R. Stafford; B. MacDonald (2009). "Acceptance of Healthcare Robots for the Older Population: Review and Future Directions". International journal of social robotics. 1 (4): 319–330. doi:10.1007/s12369-009-0030-6. Wikidata Q115258302. Hayley Robinson; Bruce Macdonald; Ngaire Kerse; Elizabeth Broadbent (2013). "The psychosocial effects of a companion robot: a randomized controlled trial". Journal of the American Medical Directors Association. 14 (9): 661–667. doi:10.1016/j.jamda.2013.02.007. PMID 23545466. Wikidata Q45166572. Elizabeth Broadbent; Liesje Donkin; Julia C Stroh (2011). "Illness and treatment perceptions are associated with adherence to medications, diet, and exercise in diabetic patients". Diabetes Care. 34 (2): 338–340. doi:10.2337/dc10-1779. PMC 3024345. PMID 21270191. Wikidata Q34507111.
COVID-19 apps include mobile-software applications for digital contact-tracing—i.e. the process of identifying persons ("contacts") who may have been in contact with an infected individual—deployed during the COVID-19 pandemic. Numerous tracing applications have been developed or proposed, with official government support in some territories and jurisdictions. Several frameworks for building contact-tracing apps have been developed. Privacy concerns have been raised, especially about systems that are based on tracking the geographical location of app users. Less overtly intrusive alternatives include the co-option of Bluetooth signals to log a user's proximity to other cellphones. (Bluetooth technology has form in tracking cell-phones' locations.)) On 10 April 2020, Google and Apple jointly announced that they would integrate functionality to support such Bluetooth-based apps directly into their Android and iOS operating systems. India's COVID-19 tracking app Aarogya Setu became the world's fastest growing application—beating Pokémon Go—with 50 million users in the first 13 days of its release. (Full article...)
m2 or 131.2 hectares. In a graphene sheet, each atom is connected to its three nearest carbon neighbors by σ-bonds, and a delocalized π-bond, which contributes to a valence band that extends over the whole sheet. This type of bonding is also seen in polycyclic aromatic hydrocarbons. The valence band is touched by a conduction band, making graphene a semimetal with unusual electronic properties that are best described by theories for massless relativistic particles. Charge carriers in graphene show linear, rather than quadratic, dependence of energy on momentum, and field-effect transistors with graphene can be made that show bipolar conduction. Charge transport is ballistic over long distances; the material exhibits large quantum oscillations and large nonlinear diamagnetism.
=== Increased MPV === Immune thrombocytopenia Disseminated intravascular coagulation Myeloproliferative disorders Administration of erythropoietin / thrombopoietin Recovery from transient hypoplasia Gray platelet syndrome GATA-1 mutation vWD Type 2B Platelet Type vWD Paris-Trousseau syndrome Mediterranean macrothrombocytopenia Bernard–Soulier syndrome MYH9-related disorders 21q11 deletion syndrome Chronic myelogenous leukemia Post-splenectomy Vasculitis Diabetes mellitus Pre-eclampsia Chronic kidney disease Respiratory diseases Thrombocytopenia secondary to sepsis Hyperthyroidism Hypothyroidism Myocardial infarction Artificial heart valves Massive hemorrhage
Sources: en.wikipedia.org
=== Design for affinity === Protein–protein interactions are involved in most biotic processes. Many of the hardest-to-treat diseases, such as Alzheimer's disease, many forms of cancer (e.g., TP53), and human immunodeficiency virus (HIV) infection involve protein–protein interactions. Thus, to treat such diseases, it is desirable to design protein or protein-like therapeutics that bind one of the partners of the interaction and, thus, disrupt the disease-causing interaction. This requires designing protein-therapeutics for affinity toward its partner. Protein–protein interactions can be designed using protein design algorithms because the principles that rule protein stability also rule protein–protein binding. Protein–protein interaction design, however, presents challenges not commonly present in protein design. One of the most important challenges is that, in general, the interfaces between proteins are more polar than protein cores, and binding involves a tradeoff between desolvation and hydrogen bond formation. To overcome this challenge, Bruce Tidor and coworkers developed a method to improve the affinity of antibodies by focusing on electrostatic contributions. They found that, for the antibodies designed in the study, reducing the desolvation costs of the residues in the interface increased the affinity of the binding pair.
=== Other === Citalopram may be used off-label to treat anxiety, and dysthymia, premenstrual dysphoric disorder, body dysmorphic disorder, and obsessive–compulsive disorder. It appears to be as effective as fluvoxamine and paroxetine in obsessive–compulsive disorder. Some data suggest the effectiveness of intravenous infusion of citalopram in resistant OCD. Citalopram is well tolerated and as effective as moclobemide in social anxiety disorder. There are studies suggesting that citalopram can be useful in reducing aggressive and impulsive behavior. It appears to be superior to placebo for behavioural disturbances associated with dementia. It has also been used successfully for hypersexuality in early Alzheimer's disease. A meta-analysis, including studies with fluoxetine, paroxetine, sertraline, escitalopram, and citalopram versus placebo, showed SSRIs to be effective in reducing symptoms of premenstrual syndrome, whether taken continuously or just in the luteal phase. For alcoholism, citalopram has produced a modest reduction alcohol intake and increase in drink-free days in studies of alcoholics, possibly by decreasing desire or reducing the reward. While on its own citalopram is less effective than amitriptyline in the prevention of migraines, in refractory cases, combination therapy may be more effective. Citalopram and other SSRIs can be used to treat hot flashes.
In 2022, Biden blocked a national railroad strike planned by multiple labor unions. During the United Auto Workers strike, he expressed support for the workers. Biden joined striking UAW workers' picket line in Michigan, becoming the first president to join a picket line. He refused to block a port strike from the International Longshoremen's Association in October 2024. Over the course of five days in March 2023, three small- to mid-size U.S. banks failed, triggering a sharp decline in global bank stock prices and swift response by regulators to prevent potential global contagion. After Silicon Valley Bank collapsed, the first to do so, Biden expressed opposition to a bailout by taxpayers. He claimed that the partial rollback of Dodd-Frank regulations contributed to the bank's failure. At the beginning of the 118th Congress, Biden and congressional Republicans engaged in a standoff after the U.S. hit its debt limit, which raised the risk that the U.S. would default on its debt. Biden and House speaker Kevin McCarthy struck a deal to raise the debt limit, the Fiscal Responsibility Act of 2023, which suspended the debt limit until January 2025. Biden signed it on June 3, averting a default. The deal was generally seen as favorable to Biden. Biden extended the COVID-19 student loan pause through September 2023, with an "on ramp" period that extended some of the pause's protections against credit reporting, collection efforts, and late payment fees through September 30, 2024.
Accumulated DNA damage appears to be a limiting factor in the determination of maximum life span. The theory that DNA damage is the primary cause of aging, and thus a principal determinant of maximum life span, has attracted increased interest in recent years. This is based, in part, on evidence in humans and mice that inherited deficiencies in DNA repair genes often cause accelerated aging. There is also substantial evidence that DNA damage accumulates with age in mammalian tissues, such as those of the brain, muscle, liver, and kidney (reviewed by Bernstein et al. and see DNA damage theory of aging and DNA damage (naturally occurring)). One expectation of the theory (that DNA damage is the primary cause of aging) is that among species with differing maximum life spans, the capacity to repair DNA damage should correlate with lifespan. The first experimental test of this idea was by Hart and Setlow who measured the capacity of cells from seven different mammalian species to carry out DNA repair. They found that nucleotide excision repair capability increased systematically with species longevity. This correlation was striking and stimulated a series of 11 additional experiments in different laboratories over succeeding years on the relationship of nucleotide excision repair and life span in mammalian species (reviewed by Bernstein and Bernstein). In general, the findings of these studies indicated a good correlation between nucleotide excision repair capacity and life span.
Sources: en.wikipedia.org
Allothreonine is an amino acid with the formula CH3CH(OH)CH(NH2)CO2H. It is the diastereomer of the amino acid threonine. Like most other amino acids, allothreonine is a water-soluble colorless solid. Although not one of the proteinogenic amino acids, it has often been the subject for the synthesis of novel proteins using an expanded genetic code. Racemic allothreonine can be produced in the laboratory from bromomethoxybutyric acid.
Iodine-129 (129I; half-life 16.1 million years) is a product of cosmic ray spallation on various isotopes of xenon in the atmosphere, in cosmic ray muon interaction with tellurium-130, and also uranium and plutonium fission, both in subsurface rocks and nuclear reactors. Artificial nuclear processes, in particular nuclear fuel reprocessing and atmospheric nuclear weapons tests, have now swamped the natural signal for this isotope. Nevertheless, it now serves as a groundwater tracer as indicator of nuclear waste dispersion into the natural environment. In a similar fashion, 129I was used in rainwater studies to track fission products following the Chernobyl disaster. In some ways, 129I is similar to 36Cl. It is a soluble halogen, exists mainly as a non-sorbing anion, and is produced by cosmogenic, thermonuclear, and in-situ reactions. In hydrologic studies, 129I concentrations are usually reported as the ratio of 129I to total I (which is virtually all 127I). As is the case with 36Cl/Cl, 129I/I ratios in nature are quite small: the pre-nuclear ratio was nearly 10−12, but as mentioned artificial sources are normally now much greater. 129I differs from 36Cl in that its half-life is longer (16.1 vs. 0.301 million years), it is highly biophilic, and occurs in multiple ionic forms (commonly, I− and IO3−), which have different chemical behaviors. This makes it fairly easy for 129I to enter the biosphere as it becomes incorporated into vegetation, soil, milk, animal tissue, etc.
=== Water treatment === Water treatment is any process that improves the quality of water to make it more acceptable for a specific end-use. Membranes can be used to remove particulates from water by either size exclusion or charge separation. In size exclusion, the pores in the membrane are sized such that only particles smaller than the pores can pass through. The pores in the membrane are sized such that only water molecules can pass through, leaving dissolved contaminants behind.
Gerry Gable (born 27 January 1937); political activist; was editor of Searchlight magazine; was member of Communist Party of Great Britain; worked as runner on Communist Party's Daily Worker newspaper; left the Communist Party because of their anti-Israel policy and because "first and foremost [he has] always been a Jewish trade unionist"; was commissioned by BBC to produce research for a BBC Panorama programme "Maggie's Militant Tendency"; was convicted in January 1964 of burglary of historian David Irving's flat Martha Gellhorn (8 November 1908 – 15 February 1998) American novelist, travel writer, and journalist who settled, retired and died in England; considered one of the great war correspondents of the 20th century. Andrew Gold (journalist) (b.1989); British Jewish journalist, YouTuber, filmmaker, author, podcaster;in 2023, Gold launched his YouTube podcast, Heretics; has written for UnHerd, Vice, Jewish News, HuffPost , Times of Israel and the BBC. Tanya Gold (born 31 December 1973) is an English journalist who has written for The Jewish Chronicle, The New York Times The Guardian, the Daily Mail, The Independent, The Daily Telegraph, The Sunday Times and the Evening Standard, and for The Spectator magazine. Vivien Goldman is a British punk rock and reggae journalist and historian, writer and musician of German Jewish ancestry.
=== Early laboratories === The earliest laboratory according to the present evidence is a home laboratory of Pythagoras of Samos. This laboratory was created when Pythagoras conducted an experiment about tones of sound and vibration of string. A 16th century underground alchemical laboratory, known as Speculum Alcemiae, was accidentally discovered in the year 2002. Rudolf II, Holy Roman Emperor was believed to be the owner. The laboratory is preserved as a museum in Prague. In the 1885 painting of Louis Pasteur by Albert Edelfelt, Pasteur is shown comparing a note in his left hand with a bottle filled with a solid in his right hand, and not wearing any personal protective equipment. Researching in teams started in the 19th century, and many new kinds of equipment were developed in the 20th century.
Sources: en.wikipedia.org
特沙莫瑞林是国际非专利名称，指一种经过 N 端修饰的生长激素释放激素类似物。它被归类为合成肽，序列与 GHRH(1-44) 密切相关。该名称不指代任何特定品牌或剂型。
监管批准集中于 HIV 感染相关的脂肪营养不良，目的是减少内脏脂肪。它未被批准用于普通肥胖或一般体重管理。不同国家的批准状态和标签范围可能不同。
长期心血管获益、死亡率影响以及停药后的持续性仍缺乏确证。部分研究提示 IGF-1 和血糖参数可能变化，但个体差异较大。这些开放问题需要更长期、更大规模的试验来回答。
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.